Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

If cultural sensitivity is not enough to reduce health disparities, what will pharmacy education do next?

Diaz-Cruz ES.

Curr Pharm Teach Learn. 2019 May;11(5):538-540. doi: 10.1016/j.cptl.2019.02.003. Epub 2019 May 3.

PMID:
31171258
2.

Enoxacin and Epigallocatechin Gallate (EGCG) Act Synergistically to Inhibit the Growth of Cervical Cancer Cells in Culture.

McDonnell AM, Pyles HM, Diaz-Cruz ES, Barton CE.

Molecules. 2019 Apr 22;24(8). pii: E1580. doi: 10.3390/molecules24081580.

3.

Differential efatutazone's impact on mammary neoplasia dependent upon Brca1 dose.

Alothman SJ, Wang W, Chao S, Kallakury BV, Díaz-Cruz ES, Furth PA.

Endocr Relat Cancer. 2018 Dec 1;25(12):L53-L57. doi: 10.1530/ERC-18-0299. No abstract available.

PMID:
30400020
4.

Comparison of tamoxifen and letrozole response in mammary preneoplasia of ER and aromatase overexpressing mice defines an immune-associated gene signature linked to tamoxifen resistance.

Dabydeen SA, Kang K, Díaz-Cruz ES, Alamri A, Axelrod ML, Bouker KB, Al-Kharboosh R, Clarke R, Hennighausen L, Furth PA.

Carcinogenesis. 2015 Jan;36(1):122-32. doi: 10.1093/carcin/bgu237. Epub 2014 Nov 23.

5.

Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation.

Cabrera MC, Tilahun E, Nakles R, Diaz-Cruz ES, Charabaty A, Suy S, Jackson P, Ley L, Slack R, Jha R, Collins SP, Haddad N, Kallakury BV, Schroeder T, Pishvaian MJ, Furth PA.

Front Oncol. 2014 May 9;4:102. doi: 10.3389/fonc.2014.00102. eCollection 2014.

6.

Association of Over-Expressed Estrogen Receptor Alpha with Development of Tamoxifen Resistant Hyperplasia and Adenocarcinomas in Genetically Engineered Mice.

Miermont AM, Cabrera MC, Frech SM, Nakles RE, Diaz-Cruz ES, Shiffert MT, Furth PA.

Anat Physiol. 2012 Jun 25;Suppl 12. pii: 001.

7.

The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Cabrera MC, Díaz-Cruz ES, Kallakury BV, Pishvaian MJ, Grubbs CJ, Muccio DD, Furth PA.

Cancer Prev Res (Phila). 2012 Jun;5(6):810-21. doi: 10.1158/1940-6207.CAPR-11-0532-T. Epub 2012 Apr 16.

8.

Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer.

Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, Cabrera MC.

Breast Cancer Res. 2011 Oct 12;13(5):220. doi: 10.1186/bcr2921. Review.

9.

Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Díaz-Cruz ES, Sugimoto Y, Gallicano GI, Brueggemeier RW, Furth PA.

Cancer Res. 2011 Aug 15;71(16):5477-87. doi: 10.1158/0008-5472.CAN-10-4652.

10.

Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Furth PA, Cabrera MC, Díaz-Cruz ES, Millman S, Nakles RE.

Ann N Y Acad Sci. 2011 Jul;1229:147-55. doi: 10.1111/j.1749-6632.2011.06086.x. Review.

11.

BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer.

Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA.

Breast Dis. 2010;32(1-2):85-97. doi: 10.3233/BD-2010-0308. Review.

12.

Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.

Nakles RE, Shiffert MT, Díaz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM, Riegel AT, Furth PA.

Mol Endocrinol. 2011 Apr;25(4):549-63. doi: 10.1210/me.2010-0114. Epub 2011 Feb 3.

13.

Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Díaz-Cruz ES, Furth PA.

Cancer Res. 2010 May 15;70(10):3965-74. doi: 10.1158/0008-5472.CAN-09-3450.

14.
15.

Evaluation of synthetic isoflavones on cell proliferation, estrogen receptor binding affinity, and apoptosis in human breast cancer cells.

Davis DD, Díaz-Cruz ES, Landini S, Kim YW, Brueggemeier RW.

J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):23-31. Epub 2007 Sep 7.

16.

Aromatase and COX in breast cancer: enzyme inhibitors and beyond.

Brueggemeier RW, Su B, Sugimoto Y, Díaz-Cruz ES, Davis DD.

J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):16-23. Epub 2007 May 25.

17.

Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer.

Díaz-Cruz ES, Brueggemeier RW.

Anticancer Agents Med Chem. 2006 May;6(3):221-32. Review.

PMID:
16712450
18.

Relationship between aromatase and cyclooxygenases in breast cancer: potential for new therapeutic approaches.

Brueggemeier RW, Díaz-Cruz ES.

Minerva Endocrinol. 2006 Mar;31(1):13-26. Review.

PMID:
16498361
19.

Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition.

Su B, Diaz-Cruz ES, Landini S, Brueggemeier RW.

J Med Chem. 2006 Feb 23;49(4):1413-9.

PMID:
16480277
20.

Lead optimization of 7-benzyloxy 2-(4'-pyridylmethyl)thio isoflavone aromatase inhibitors.

Su B, Hackett JC, Díaz-Cruz ES, Kim YW, Brueggemeier RW.

Bioorg Med Chem. 2005 Dec 1;13(23):6571-7. Epub 2005 Aug 24.

PMID:
16125392
21.

Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.

Brueggemeier RW, Díaz-Cruz ES, Li PK, Sugimoto Y, Lin YC, Shapiro CL.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):129-36.

PMID:
15964185
22.

Aromatase inhibitors in the treatment of breast cancer.

Brueggemeier RW, Hackett JC, Diaz-Cruz ES.

Endocr Rev. 2005 May;26(3):331-45. Epub 2005 Apr 6. Review.

PMID:
15814851
23.

Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells.

Díaz-Cruz ES, Shapiro CL, Brueggemeier RW.

J Clin Endocrinol Metab. 2005 May;90(5):2563-70. Epub 2005 Feb 1.

PMID:
15687328
24.

Role of the azinomycin naphthoate and central amide in sequence-dependent DNA alkylation and cytotoxicity of epoxide-bearing substructures.

Coleman RS, Burk CH, Navarro A, Brueggemeier RW, Diaz-Cruz ES.

Org Lett. 2002 Oct 3;4(20):3545-8.

PMID:
12323065

Supplemental Content

Loading ...
Support Center